Chamwe Kaira
Mediclinic Holdings Limited reported solid revenue and earnings growth for the year ended 31 March 2026, even as the healthcare group navigates major restructuring plans.
Although Mediclinic is no longer required to publish standalone results following its acquisition by a consortium comprising Remgro Limited and MSC Mediterranean Shipping Company Holding SA, Remgro said the disclosure was made due to the group’s significant contribution to its own financial position and net asset value.
Group adjusted revenue rose 11% to US842 million. The EBITDA margin improved to 15.7% from 15.3% in the prior year, and adjusted earnings increased 45% year-on-year.
In constant currency terms, revenue and EBITDA grew 5% and 8% respectively, reflecting broad-based growth across divisions.
Despite strong operational gains, earnings were affected by significant non-cash impairment charges.
These included a US689 million in write-downs on property, equipment, vehicles and intangible assets in Switzerland.
Mediclinic said the impairments reflect increasingly difficult market conditions and are excluded from its adjusted earnings measure.
The results come as Remgro and Investment Holding Limited SARL, a subsidiary of MSC, advance a major restructuring of their stakes in Mediclinic.
Under an agreement signed on 30 March 2026, Remgro will acquire full ownership of Mediclinic Southern Africa, including its operations in Namibia, for US950 million.
The restructuring is expected to significantly reshape Mediclinic’s geographic and operational footprint, separating its Southern African and Swiss businesses between its major shareholders.
Remgro said the underlying performance demonstrates continued resilience in Mediclinic’s operating model, driven by volume growth and efficiency improvements, even as certain markets remain under pressure.
The group added that further details, including divisional breakdowns and reconciliations, are available through its investor relations platform.
